New Home2026-05-21T14:39:16+10:00

Transform Your Response

Transform Your Response

Patient-Led. Built From Lived Experience.

Learn to keep options open.

Keep options open

Where Patients Lose

The Patient Survival System

Biliary 101

Why This Foundation Exists

I am a late-stage 4 cholangiocarcinoma survivor and co-founder of Cholangiocarcinoma Foundation Australia alongside my wife, Claire.

What most patients need in that moment is not reassurance alone.

They need orientation.
What matters now.
What comes next.

That is why this Foundation exists.

Everything we build is designed around one goal:

Improving today’s patient survival – today.

View my bio

Just yesterday, I was a person. Today, I am a patient.
I must become the best patient I can be, so that I can become that person again.

Steve

Our People Our Community Our Culture

906, 2025

FGFR2 Mutation Drives Cholangiocarcinoma

By |

FGFR2 mutation drives cholangiocarcinoma by trigger nonstop cell growth by fusing two genes into a rogue hybrid. This article explains how the mutation forms, what goes wrong, and how therapies like Pemigatinib and Futibatinib work to shut down the chaos and restore balance.

Testimonials

Go to Top